Inventor

ZHOU CHANGYOU

US46 patents

⚠️ This page may combine multiple inventors who share the name “ZHOU CHANGYOU”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

ZHOU CHANGYOU

BEIGENE LTD

Treatment cancers using a combination comprising PARP inhibitors

Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors

Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer

Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors

Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors

Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones

5 or 8-substituted imidazo[1,5-a]pyridines as indoleamine and/or tryptophane 2,3-dioxygenases

Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors

Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore

5 or 8-substituted imidazo[1, 5-a] pyridines as indoleamine and/or tryptophane 2, 3-dioxygenases

Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors

Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors

Fused tricyclic compounds as Raf kinase inhibitors

Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors

Fused tricyclic compounds as Raf kinase inhibitors

Process for preparing a PARP inhibitor, crystalline forms, and uses thereof

Fused tricyclic amide compounds as multiple kinase inhibitors

Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer

Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases

5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases

Crystalline forms of salts of fused penta-cyclic dihydrodiazepinocarbazolones, and uses thereof

Stable solid dispersion of a B-RAF kinase dimer inhibitor, methods of preparation, and uses therefor

Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist

Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones

Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist

MERCK & CO INC

Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity

Gamma-aminoamide modulators of chemokine receptor activity

Tetrahydropyranyl cyclopentyl heterocyclic amide modulators of chemokine receptor activity

Tetrahydropyranyl cyclopentyl benzylamide modulators of chemokine receptor activity

Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity

Somatostatin agonists

Process for the preparation of CCR-2 antagonists

Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity

Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity

2,6-disubstituted piperiddines as modulators

Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity

MERCK SHARP & DOHME

Antidiabetic bicyclic compounds

Antidiabetic bicyclic compounds

Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity

Substituted pyrimidines

Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity

Substituted pyrimidines

ZHOU CHANGYOU

Substituted cycloocta[5,6]pyrido[4,3,2-de]phthalazines as PARP inhibitors

Fused tricyclic compounds as Raf kinase inhibitors

Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors

Substituted pyrimidines